{
  "docId": "019de077-19d1-772e-933a-c7f1c42d9b04",
  "docSlug": "d223628377f56d072b5dbf426c21baf1",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 42,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "The slide provides a detailed breakdown of patient enrollment across different dose cohorts (25mg to 125mg QD) for the ARROS-1 trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-19d1-772e-933a-c7f1c42d9b04/31",
  "deckHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04",
  "deckJsonHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04.json",
  "deckAnchorHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.35,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "PHASE 1 DOSE-ESCALATION. Phase 1 enrollment completed August 2023: Updated data to be presented at a medical meeting in 2024. PATIENT POPULATION. OBJECTIVES.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ec691f7-d181-4e53-af3c-56e8d78be61d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.4,
        "y": 0.7
      },
      "kind": "source-note",
      "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; mg, milligram; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; QD, once daily; RP2D, recommended phase 2 dose; ROS1+, ROS1-positive; TKI, tyrosine kinase inhibitor. a Patients with baseline concurrent oncogenic drivers identified on subsequent testing and patients without measurable disease are excluded from efficacy evaluation per prespecified protocol analysis plan. b First response evaluation is pending for 6 patients. Response evaluable population prospectively defined as all NSCLC patients with measurable disease, without concurrent oncogenic driver, and who undergo ≥1 post-baseline response assessment (or discontinue treatment due to clinical progression/death prior to the first response assessment). Additional patients unevaluable for response: no measurable disease at baseline (n = 3); tumor with alternate oncogenic driver (MET amplification, BRAF V600E) (n = 3); voluntarily discontinued study treatment prior to first response assessment (n = 1); other solid tumor (pancreatic cancer) (n = 1). Source: Drilon A. et al., EORTC-NCI-AACR 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f5dea54-fe20-4fcd-998d-3ceb378dabd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.4,
        "y": 0.3
      },
      "kind": "table",
      "text": "Zidesamtinib Dose Cohorts, All Doses, 25 mg QD, 50 mg QD, 75 mg QD, 100 mg QD, 125 mg QD. BOIN Dose-Escalation, N=15, 3, 3, 3, 3, 3. Expansion, N=20, 6, 1, 6, 7, 0. All-Treated Population, N=35, 9, 4, 9, 10, 3. NSCLC Response-Evaluable Population, N=21, 7, 2, 5, 4, 3.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9226058d-c29f-41cb-90e0-fca5184cf8df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ARROS-1: A Global First-in-Human Phase 1/2 Clinical Trial of Zidesamtinib in Advanced ROS1-Positive NSCLC and Other Solid Tumors (NCT05118789)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "828ff955-a7a3-460a-a9a4-28847320f765",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}